Have a feature idea you'd love to see implemented? Let us know!

DYN Dyne Therapeutics Inc

Price (delayed)

$28.74

Market cap

$2.89B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$3.59

Enterprise value

$2.3B

Dyne Therapeutics, Inc. operates as a biotechnology company. The Company focuses on transforming the lives of people with serious diseases by developing muscle-targeted therapies. Dyne Therapeutics offers its services in ...

Highlights
Dyne Therapeutics's quick ratio has soared by 153% YoY and by 29% from the previous quarter
The equity has soared by 62% from the previous quarter
DYN's EPS is up by 10% since the previous quarter but it is down by 6% year-on-year
DYN's net income is down by 36% YoY

Key stats

What are the main financial stats of DYN
Market
Shares outstanding
100.4M
Market cap
$2.89B
Enterprise value
$2.3B
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
3.24
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Earnings
Revenue
$0
EBIT
-$257.6M
EBITDA
-$255.35M
Free cash flow
-$220.31M
Per share
EPS
-$3.59
Free cash flow per share
-$2.38
Book value per share
$8.87
Revenue per share
$0
TBVPS
$8.93
Balance sheet
Total assets
$825.88M
Total liabilities
$50.69M
Debt
$25.72M
Equity
$775.19M
Working capital
$762.57M
Liquidity
Debt to equity
0.03
Current ratio
26.63
Quick ratio
26.24
Net debt/EBITDA
2.29
Margins
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Efficiency
Return on assets
-60%
Return on equity
-68.9%
Return on invested capital
-186.3%
Return on capital employed
-32.4%
Return on sales
N/A
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

DYN stock price

How has the Dyne Therapeutics stock price performed over time
Intraday
-0.42%
1 week
-6.48%
1 month
-17.32%
1 year
293.7%
YTD
116.09%
QTD
-19.99%

Financial performance

How have Dyne Therapeutics's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$271.08M
Net income
-$257.6M
Gross margin
N/A
Net margin
N/A
DYN's operating income is down by 39% YoY
DYN's net income is down by 36% YoY

Growth

What is Dyne Therapeutics's growth rate over time

Valuation

What is Dyne Therapeutics stock price valuation
P/E
N/A
P/B
3.24
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
DYN's EPS is up by 10% since the previous quarter but it is down by 6% year-on-year
The equity has soared by 62% from the previous quarter
The price to book (P/B) is 39% lower than the last 4 quarters average of 5.3 but 8% higher than the 5-year quarterly average of 3.0

Efficiency

How efficient is Dyne Therapeutics business performance
The return on equity is up by 38% since the previous quarter and by 13% year-on-year
The company's return on assets rose by 33% QoQ and by 9% YoY
DYN's return on invested capital is down by 23% year-on-year but it is up by 22% since the previous quarter

Dividends

What is DYN's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for DYN.

Financial health

How did Dyne Therapeutics financials performed over time
Dyne Therapeutics's quick ratio has soared by 153% YoY and by 29% from the previous quarter
Dyne Therapeutics's current ratio has soared by 153% YoY and by 22% from the previous quarter
The debt is 97% smaller than the equity
Dyne Therapeutics's debt to equity has shrunk by 79% YoY and by 50% QoQ
The equity has soared by 62% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified. Data from and Sharadar.